Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

December 03, 2018   |   December 2018 Bond Updates
OSLO, Dec. 3, 2018 /PRNewswire/ -- Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL) Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and...

View more at:
Related News
Home| About us | Contact us